LivaNova PLC (NASDAQ:LIVN) Receives $74.78 Average PT from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $74.7778.

LIVN has been the topic of several research reports. The Goldman Sachs Group restated a “neutral” rating and set a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Needham & Company LLC raised their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Mizuho lifted their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Barclays boosted their target price on shares of LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Finally, Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research report on Wednesday, February 25th.

Institutional Trading of LivaNova

A number of institutional investors and hedge funds have recently bought and sold shares of LIVN. Envestnet Asset Management Inc. increased its stake in LivaNova by 168.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock valued at $1,421,000 after purchasing an additional 17,007 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of LivaNova in the third quarter valued at $7,687,000. LSV Asset Management lifted its stake in shares of LivaNova by 25.4% in the third quarter. LSV Asset Management now owns 674,610 shares of the company’s stock valued at $35,336,000 after buying an additional 136,600 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its holdings in shares of LivaNova by 8.1% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock valued at $18,315,000 after buying an additional 26,202 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of LivaNova by 79.6% during the second quarter. New York State Common Retirement Fund now owns 86,741 shares of the company’s stock valued at $3,905,000 after buying an additional 38,451 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

NASDAQ LIVN opened at $61.85 on Monday. The firm’s fifty day moving average price is $64.91 and its two-hundred day moving average price is $60.17. The stock has a market cap of $3.38 billion, a PE ratio of -13.87 and a beta of 0.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.16 and a current ratio of 1.36. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $71.92.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $360.92 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.LivaNova’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, equities analysts expect that LivaNova will post 2.85 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.